Vaccine bottle with syringe in the top

Oxford vaccine becomes first to publish data in peer-review literature

In another significant step forward in the development of an effective vaccine to combat the Covid-19 virus, a vaccine candidate being developed by the University of Oxford has published data from its clinical trial in peer-review literature.

Publishing in The Lancet, it becomes the first vaccine candidate worldwide to publish the results of its phase 3 trial in a peer-reviewed journal; typically seen as a mark of validity for the data gathered.

The research team for the NIHR-funded and supported vaccine have presented a pooled analysis of phase 3 trials of a vaccine against Covid-19 across two different dose regimens, resulting in an overall vaccine efficacy of 70.4% at least 14 days after the second dose.

The sub-group receiving two standard doses showed 62.1% efficacy, while the sub group with one low dose and one standard dose demonstrated 90.0% efficacy.

This data draws on 11,636 volunteers across the UK and Brazil, and combined across the three groups of people vaccinated.

No hospitalisations or severe disease were observed among participants in any of the vaccinated groups.

Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: “Today, we have published the interim analysis of the phase III trial and show that this new vaccine has a good safety record and efficacy against the coronavirus.

“We are hugely grateful to our trial volunteers for working with us over the past eight months to bring us to this milestone.”

Professor Sarah Gilbert, Professor of Vaccinology at the University of Oxford, added: ““We have known for many years that adenoviral vectored vaccines fulfil the requirements for use against outbreak or pandemic diseases.

“They are safe, highly immunogenic, can be manufactured in large quantities at low cost and do not require frozen storage.

“Following the demonstration of vaccine efficacy in many preclinical studies, we now have clear evidence of efficacy in the trial results presented in a peer-reviewed publication today.

“Now under regulatory review, we hope that this vaccine will shortly be in use to start saving lives.”

Researchers also investigated the potential for the vaccine to prevent asymptomatic disease, through the use of weekly swabbing by UK trial volunteers.

The initial data from this appears to indicate that the low dose / standard dose vaccine may provide a protection against asymptomatic infection, but stress that these data are at an early phase, with too high a level of uncertainty to be certain that this vaccine will protect against asymptomatic infection.

NHE Sept/Oct 21

NHE Sept/Oct 21

Improving care for long-term conditions

Join us in our September/October edition of National Health Executive, as we explore a range of topics impacting and improving the care that we can deliver to patients, the facilities within which we deliver them, and the opportunities in the digital space to accent and evolve our care capabilities

Videos...

View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Digital Healthcare

The integration of new technology, such as using virtual outpatient appointments instead of face-to-face reviews of patients in the hospital. Adapting the ways in which our NHS workers serve people has been critical in continuing to provide high-quality treatment, a positive patient experience and preventing Covid-19 transmission during the pandemic. Our healthcare sector has the potential to transform the way we continue to provide essential services while also improving patient care. But how easy is the integration of these innovations into routine NHS practice?

On the 28th of October, at the NHE365 Virtual Hospitals & Technology Enabled Care online event, we will be discussing patient flow and experience, reducing waiting times, reducing the patient backlog and increasing technology adoption. Will you be attending? 

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all